SOUTH SAN FRANCISCO, Calif.–BUSINESS WIRE–Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced it has completed a $120 million private financing of Convertible Notes. Participants in this financing were primarily first-time investors in Allogene. The financing was led by Perceptive Advisors and included Deerfield Management …
Apellis Pharmaceuticals Announces $60 Million Series E Financing
Funding Will Advance Trials of APL-2 in Paroxysmal Nocturnal Hemoglobinuria LOUISVILLE, KY., August 10, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced the closing of a $60 million Series E preferred stock financing led by Sectoral Asset Management. New …
Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor
Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor RESEARCH TRIANGLE PARK, NORTH CAROLINA — (Marketwired) — 06/08/17 — Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the “Company” or “Fennec”), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric …
Corvus Pharmaceuticals Completes $75 Million Series B Financing
Funds will Advance Company’s Immuno-Oncology Small Molecule and Antibody Programs Burlingame, CA, September 29, 2015 – Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development of novel agents targeting the immune system to treat patients with cancer, today announced that it closed a $75 million Series B financing. The transaction was led by …
Oncobiologics Secures $31 Million Financing
Releasefaa9345b-168e-47b5-8d3e-2b4b4a581492_2150864.pdf Cranbury, NJ – July 27, 2015 — Oncobiologics, Inc.,announced the closing of a $31 million financing. Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs. The investment round was led by new investor, Perceptive Advisors. Participating new investors …
+1 212.937.4970